Xiaoyin Lu, Jiheng Hao

(Shandong First Medical University)

Abstract：

Obstructive hypertrophic cardiomyopathy ( OHCM) is an autosomal dominant genetic disease characterized by asymmetric hypertrophy of the interventricular septum. Traditional treatment methods mainly focus on improving symptoms and lack specific drugs for hemodynamic change caused by obstruction. With the deepening of research on the disease and the progress of drug development , drugs based on the pathophysiology of obstructive hypertrophy—Cardiac myosin inhibitors have emerged. Current experimental results show that cardiac myosin inhibitors can effectively reduce left ventricular outflow tract obstruction , improve patients ’New York Heart function assessment and quality of life. The short⁃term efficacy and safety of the drug have been confirmed , but the long⁃term efficacy is currently being evaluated in clinical trials. This article reviews the mechanism of cardiac myosin inhibitors in OHCM , combined with recent clinical trial results and the treatment status of OHCM in the future.

Key Words：

obstructive hypertrophic cardiomyopathy; cardiac myosin inhibitors; outflow tract obstruction; short⁃term outcome